Since moderate to severe anemia typically develops from CKD stage IIIb–IV onward, and most patients enrolled in randomized clinical trials testing SGLT2 inhibitors were not in stage IV or V CKD, there is limited information on the potential benefits of SGLT2 inhibitors in severe anemia. Here, SLC5A2 is linked to chronic kidney disease.